|
Published by: Decision Resources
Published: Dec. 27, 2007 - 39 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- 2007 in Review
- Looking for the Grail
- Noteworthy 2007 News and Events That Signifi cantly Impact the Pharmaceutical Industry
- 2007’s Problems with Drug Safety
- Big Pharma’s Ongoing Productivity Problems
- Ramifi cations of Biogenerics Entering the Marketplace
- Ramifi cations of Patent Expiries
- Ascendancy of Specialty Pharma and Biotech
- Retrenching and Choosing Wisely
- Blockbuster Numbers Creep Upward, but Growth Grinds Almost to a Halt
- Executing Change Requires a Holistic Approach to Managing a Company
- A Tale of Two Management Styles: Pfi zer Versus Schering-Plough
- Management Style
- Insights from the Asenapine Story
- Lessons to Be Learned About Management
- Choosing Wisely Has Never Been More Important
- Jumping on Technology Opportunities
- The Quest for Innovation: Valuable Technology Opportunities, Circa 2007
- Future Lifeblood of the Pharmaceutical Industry
- New Value Propositions: Value-for-Money
- Increasing Power of Activist States
- 2007 Lessons to Be Learned
- 2007 State Legislative Bills
- State Attorneys General Not Afraid to Litigate
- 2007 Spectrum Scorecard
- Showcase of Decision Resources, Inc., Reports and Presentations
- Tables
- 1. Products Gaining Blockbuster Status, 2006
- 2. The New Mantra: A Strategy of Focus, Late 2006-2007
- 3. State Activities That Will Impact the Pharmaceutical Industry Going Forward
- 4. Spectrum Scorecard: Pharmaceutical Industry Performance, 2007
- Figures
- 1. The Perceived Value of Biotech Is Real: Growth in AMEX Indices, 2004-2007
- 2. Growth in the Number of Global Blockbusters, 1987-2006
- 3. Years on the Market to Reach Blockbuster Status
- 4. Components Central to Executing Change in a Pharmaceutical Company
- 5. U.S. Oncology Leaders, 2000 and 2005
- 6. A Blazing Mergers and Acquisition Trail for Antibody Companies, 2005-2007
- 7. Prescription Drug State Legislation, 2007
- Experts Featured
- John Ansell, M.A., principal, John Ansell Consultancy
- Sarah Fuller, president, Decision Resources, Inc.
- Barrie G. James, Ph.D., principal, Pharma Strategy Consulting
- Decision Resources, Inc., Analysts Featured
- Mary Argent-Katwala, Ph.D., therapeutic area director, Oncology
- Sandra T. Chow, Ph.D. candidate, analyst, Cognos
- Danielle Drayton, Ph.D., analyst, Infectious Disease
- Greg Dwyer, M.B.A., analyst, Immune and Infl ammatory Disorders and Mosaic
- John Earl, M.Sc., Ph.D., principal therapeutic area director, Cardiology and Oncology
- Sylvia Eash, Ph.D., analyst, Infectious Disease
- Jeremy Goldman, M.D., analyst, Cardiology
- Neil Grubert, M.A., director of pricing and reimbursement, Spectrum, Pharmacoeconomics, Pricing, and Reimbursement
- Ramya Kollipara, Ph.D., analyst, Oncology
- James McDermott, vice president, consulting
- Andrew Merseth, senior business analyst
- Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy Markets and Emerging Technologies
- Chris Schutz, M.B.A., Ph.D., senior analyst, Millennium Research Group, a Decision Resources, Inc., company
- Prachi Vora, M.P.H., program manager, Spectrum, Biomarkers and Diagnostics
- Donny Wong, Ph.D., senior analyst, Metabolic Disorders
AbstractModerate successes and "business as usual" characterize the performance of the pharmaceutical industry in 2007. In this year-end retrospective report, we contemplate the importance of key events and achievements in the industry. We asked industry-leading experts to identify particularly noteworthy events in 2007 and lessons that can be learned for 2008. Six themes emerged; our experts discuss their implications for the industry. Furthermore, we offer a Spectrum Scorecard that assesses industry performance in a variety of critical areas.
Get the Answers You Need to Shape Your Strategy
- The pharmaceutical industry may never be to return to its glory days, but it can exert control over its future through the strategies and changes that it is willing to adopt today. What strategic options are essential to achieve success in today's evolving markets? What are the future implications of these changes for pharmaceutical companies?
- Pharmaceutical companies must ensure they are "fit for purpose" in today's business environment. What strategies can pharmaceutical management pursue to capture and harness the essence of a results-oriented business and make their companies truly fit for purpose? How can they uncover previously unrealizable profits and growth and also differentiate themselves so that they can grasp valuable competitive advantage?
Scope
- 2007 in review: a retrospective on news and key themes from the year.
- Seeking a new vision for the pharmaceutical industry: looking for the Holy Grail of opportunity.
- Negative industry impacts: from generics erosion, biogenerics, declining productivity, and drug safety concerns combined with the increased importance of specialty pharma and biotech.
- New strategies needed for future success: rethinking the blockbuster strategy, a holistic approach to management style, fit with strategy, choosing strategies and opportunities wisely.
- Jumping on technology opportunities: identifying key technologies and turning innovation into new products and services.
- New value propositions: value-for-money.
- Growing influence of U.S. states: legislative bills, litigation by state attorneys general, lessons learned.
- 2007 industry report card: how successful was Big Pharma in capitalizing on the many opportunities available in 2007?
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
